Background:
Congenital heart disease in children with pulmonary hypertension is a common and serious complication, which has a direct impact on the surgical effect and prognosis of children. Bosentan and vardenafil are commonly used drugs for the treatment of postoperative pulmonary hypertension in children with congenital heart disease, and there are few clinical studies on their combined use. Therefore, the purpose of this randomized controlled trial is to evaluate the effectiveness and safety of the combined use of 2 drugs in the treatment of postoperative pulmonary hypertension in children with congenital heart disease.
Methods:
This is a prospective randomized controlled trial to study the effectiveness and safety of bosentan combined with vardenafil in the treatment of postoperative pulmonary hypertension in children with congenital heart disease. Approved by the clinical research ethics committee of our hospital. The patients were randomly divided into 1 of 2 treatment regimens:
Patients, doctors, nurses, and data collection assistants were blinded to group allocation. Observation indicators include: oxyhemoglobin saturation (SpO2), 6-min Walking Test Distance (6 MWTD), systolic pulmonary artery pressure, mean pulmonary artery pressure, Borg score, NYHAFC score, etc. Data were analyzed using the statistical software package SPSS version 25.0 (Chicago, IL).
Discussion:
This study will evaluate the effectiveness and safety of bosentan combined with vardenafil in the treatment of pulmonary hypertension after congenital heart disease in children. The results of this experiment will provide a clinical basis for the use of bosentan combined with vardenafil to treat pulmonary hypertension after congenital heart disease in children.
Ethics and dissemination:
Private information from individuals will not be published. This systematic review also does not involve endangering participant rights. Ethical approval was not required. The results may be published in a peer-reviewed journal or disseminated at relevant conferences.
OSF Registration number:
DOI 10.17605/OSF.IO/962BT.
As times go by, people’s standard of living is constantly improving, but the medical pressure exerted by children with cerebral palsy is also increasing and the recovery of lower limb function in children with cerebral palsy after treatment has also gets people’s attention. Of course, the relevant medical equipment is constantly improving, especially the appearance of virtual reality technology, which has played an extremely important role in restoring the lower extremities of children with cerebral palsy. In order to study the role that virtual reality technology can play in children with cerebral palsy, this article collects relevant information, builds a case template, and uses comprehensive quantification by investigating patients, examining relevant documents, and interviewing professionals. With qualitative analysis, a damage assessment matrix is created. Experimental results prove that the use of virtual reality technology can improve the treatment efficiency of children with cerebral palsy by more than 30%. In terms of the rehabilitation effect of children’s lower limb function, virtual reality technology is more targeted for the treatment of children with far-reaching effects. It is much higher than traditional treatment methods, and the mobility of the children’s lower limbs is restored by more than 80%. This shows that virtual reality technology can play an important role in the rehabilitation of the lower limbs of children with cerebral palsy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.